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Abstract
Purpose The aim of this study was to compare the risk of
chemotherapy-induced nausea and vomiting (CINV) events
for various 5-HT3 RAs in patients who received moderately
(MEC) or highly emetogenic chemotherapy (HEC) by
evaluatinghospitaloremergencydepartment(ED)admissions.
Methods PharMetrics claims database was used to identify
patients diagnosed with breastcancer (BC) who were initiated
on cyclophosphamide-based adjuvant chemotherapy or with
lung cancer (LC) initiated on carboplatin-based or cisplatin-
based chemotherapy between 2005 and 2008. Patients were
stratified in two groups: those initiated and maintained on
palonosetron versus those treated with any other 5-HT3 RA
regimens in the 6-month post first chemotherapy. Risk for
CINVevents, identified by ICD-9-CM for nausea, vomiting,
and/or dehydration, were estimated using logistic regres-
sions, controlling for age, gender, comorbidity, and total
chemotherapy doses or days.
Results Of the 4,868 cyclophosphamide-treated BC, 5,414
carboplatin-treated LC, and 1,692 cisplatin-treated LC iden-
tified, there were1,864 BC(38.5%),1,806carboplatin-treated
LC (33.4%), and 390 cisplatin-treated LC (23.0%) in the
palonosetron-only group. Palonosetron-only group had sig-
nificantly lower probability of CINV events associated with
ED/hospital admissions in all three cohorts (3.5% vs. 6.3% in
BC, 9.5% vs. 13.8% in carboplatin-treated LC, and 16.4% vs.
22.6% in cisplatin-treated LC, all at p<0.05). Logistic
regressions found palonosetron-only group had significantly
lower risk of CINV events (odds ratios=0.550, 0.653, and
0.689 in BC, carboplatin-treated LC and cisplatin-treated LC,
respectively, p<0.05).
Conclusion Patients with lung or breast cancer receiving
MEC or HEC had significantly lower risk of CINV events
associated with hospital/ED admissions if initiated and
maintained on palonosetron relative to patients receiving 5-
HT3 RA regimens.
Keywords CINV.5-HT3 RAs.Palonosetron.Comparative
effectiveness
Introduction
Antiemetics including the 5-hydroxytryptamine receptor
antagonists (5-HT3 RAs) have been used predominantly to
improve the prophylaxis of chemotherapy-induced nausea
and vomiting (CINV) in patients placed on moderately
(MEC) or highly emetogenic (HEC) chemotherapy [1, 2].
Palonosetron (Aloxi®), a newer 5-HT3 RA, was approved
in the USA in 2003 for the prevention of acute and delayed
CINV in patients with cancer receiving MEC or HEC [3].
Palonosetron is a potent and highly selective 5-HT3 RA
with strong binding affinity to the receptor and a longer
plasma elimination half-life of about 40 h as compared to
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DOI 10.1007/s00520-011-1165-1the older 5-HT3 RAs [3]. Palonosetron also exhibits
allosteric interactions, triggers receptor internalization,
differentially inhibits “crosstalk” between NK-1 receptors
and 5-HT3 signaling pathways, and exhibits prolonged
inhibition of receptor function [4, 5]. Palonosetron is the
first and the only agent in the class that is approved for
preventing both delayed and acute emesis induced in
patients receiving MEC [6, 7].
In four phase III trials, palonosetron was reported to have
improved efficacy relative to the older 5-HT3 RAs in the
prevention of nausea and vomiting associated with initial and
repeat courses of MEC or HEC [2, 8–10]. Gralla and
colleagues evaluated patients randomized to receive single
intravenous (i.v.) palonosetron doses of 0.25 or 0.75 mg, or
ondansetron (32 mg), before initiating MEC. Palonosetron at
0.25 mg was significantly superior to ondansetron in the
prevention of acute and delayed CINV events. Complete
response rates were significantly higher for palonosetron-
treated patients during the acute phase (81.0% vs. 68.6%), the
delayed phase (74.1% vs. 55.1%), and the overall phase
(69.3% vs. 50.3%) [8]. In the second MEC trial, Eisenberg et
al. reported on a multicenter, double-blind, phase III study in
patients who were randomized to receive i.v. palonosetron
doses of 0.25 or 0.75 mg, or dolasetron (100 mg) before
initiating MEC [9]. Complete response rates were significantly
higher for palonosetron during the acute phase (63.0% and
52.9% for 0.25 mg palonosetron and dolasetron, respectively),
the delayed phase (54.0% and 38.7%, respectively), and the
overall phase (46.0% and 34.0%, respectively).
The Aapro et al. study [2] was one of the two phase III
trials that studied the efficacy and safety of palonosetron in
preventing CINV following HEC. Single-dose palonosetron
was found as efficacious as ondansetron in preventing acute
CINV. Moreover, palonosetron was significantly more effica-
cious than ondansetron during the delayed (42.0% vs. 28.6%)
and the overall phases (40.7% vs. 25.2%) when patients were
pre-treated with dexamethasone [2]. In a second phase III
HEC trial carried out in Japan, patients with cancer and
treated with HEC were randomly assigned to either single-
dose palonosetron (0.75 mg) or granisetron (40 mcg/kg) given
30 min before HEC on day 1. Reported results indicated that
when palonosetron was administered with dexamethasone
before HEC, it exerted efficacy against CINV which was non-
inferior to that of granisetron in the acute phase and better
than that of granisetron in the delayed phase, with a
comparable safety profile for the two treatments [10].
While the efficacy of palonosetron in preventing CINV
events has been well documented in clinical trials, its
effectiveness in the real-world clinical practice has not been
systematically reported. Hence, the present study was
performed with a large claims database to investigate the
comparative effectiveness of palonosetron versus other 5-
HT3 RAs as prophylaxis for resource-intensive CINV
events associated with hospital and/or emergency depart-
ment (ED) admissions in patients with breast or lung cancer
receiving MEC or HEC. The secondary objective was to
compare the effectiveness results reported in this study with
the efficacy data previously reported in phase III clinical
trials.
Study patients and methods
The study population was selected from PharMetrics data-
base, which compiles integrated managed care pharmacy and
medical claims of over 2 billion inpatient and outpatient
transactions from 60 million members nationwide. The study
included one cohort of patients diagnosed with breast cancer
who received adjuvant chemotherapy with cyclophosphamide
within 4 months after surgery. The other two cohorts included
patients diagnosed with lung cancer who were initiated on
either carboplatin or cisplatin-based chemotherapy within the
study time frame (January 1, 2005 and June 30, 2008).
Figures 1 and 2 depict the selection process for patients with
breast cancer and lung cancer. Based on doses used and/or
the published literature, the breast cancer and the
carboplatin-treated lung cancer cohorts were considered
MEC-treated. The cisplatin-treated lung cancer cohort was
considered as HEC-treated.
The study index date was defined as the date of breast
cancerdiagnosisforthebreastcancercohortorthefirstdateof
chemotherapy with carboplatin/cisplatin for the lung cancer
cohorts. The index chemotherapy was the first chemotherapy
treatment cycle, while the index chemotherapy date was
marked as the first date of the index chemotherapy.
Patients with breast cancer were identified using the
International Classification of Diseases-Clinical Modifica-
tion, 9th Revision (ICD-9-CM) codes (174.xx), while those
with lung cancer were identified by ICD-9-CM codes of
162.xx. National Drug Codes and Healthcare Common
Procedure Coding System (HCPCS) codes were used to
identify chemotherapeutic agents. Selected patients were
≥18 years of age with records of claims for ≥6 months prior
to study index date. Patients who received cyclophospha-
mide, carboplatin, or cisplatin within 6 months prior to
index chemotherapy were excluded. Additional inclusion
criteria consisted of no prior history of vomiting, nausea, or
dehydration identified by ICD-9-CM codes for 6 months
prior to the index chemotherapy date and that patients must
have had ≥6-month follow-up period after the index
chemotherapy date. Study duration was defined as 6 months
from the index chemotherapy.
Investigated antiemetics included dolasetron, granisetron
and ondansetron, palonosetron, aprepitant, and dexametha-
sone. Patients were stratified into two groups, with one
consisting of patients initiated and maintained on palonose-
tron as the only 5-HT3 RA antiemetic (palonosetron-only
942 Support Care Cancer (2012) 20:941–949group). The other group included patients who were
initiated on one of the older 5-HT3 RAs and maintained
on the same agent or alternated throughout the study
duration between the older 5-HT3 RAs and palonosetron,
either as single agents or in combinations. The use of
aprepitant and dexamethasone was accounted for in both
study groups.
Comorbidities for the 6-month baseline period prior to
the study index date were calculated using the Charlson
Comorbidity Index (CCI) [11, 12]. CINV events associated
with hospital/ED admissions were extracted using claims
with ICD-9-CM codes for nausea, vomiting, and/or
dehydration (787.0, 787.01, 787.02, 787.03, 276.5,
276.50, 276.51, and 276.52). Cyclophosphamide doses
per square meter per cycle, or total cisplatin/carboplatin
treatment days for the study duration, were calculated. Age
and gender of patients were also considered.
Statistical analyses
Meansandstandarddeviationswerecalculatedforcontinuous
variables witht tests performed to compare the palonosetron-
only to the other 5-HT3 RA regimen-treated groups. Sample
sizes and frequency distributions were reported for categor-
ical variables with chi-square results. Separate multivariate
logistic regressions were performed for the three cancer
cohorts to compare the risk of experiencing hospital/ED-
associated CINV events (dependent variable) between the
two study groups, controlling for differences in age, CCI
score, gender (lung cancer), cyclophosphamide dose per
square meter per cycle (breast cancer), and cisplatin/
carboplatin treatment days (lung cancer).
To compare the clinical effectiveness of palonosetron
estimated from the current study and efficacy estimated from
previous clinical trials, the relative risks, absolute risk
reductions, and relative risk reductions of CINVevents were
computed. Moreover, the adjusted relative risks and relative
risk reductions were computed based on odds ratios (ORs)
from multiple logistic regression models and baseline inci-
dences of outcome estimated in the current study [13]. All
statistical analyses were carried out using SAS 9.0 statistical
software (SAS Institute, Inc, Cary, NC, USA).
Results
Characteristics of the study cohorts
A total of 4,868 female patients with breast cancer were
identified. For the study duration, 43.1% were treated with
5-HT3 RA antiemetic prophylaxis only, 25.0% were treated
with 5-HT3 RAs in combination with dexamethasone,
11.8% were treated with 5-HT3 RAs in combination with
aprepitant, and 20.1% were treated with combination of a 5-
HT3 RA, dexamethasone, and aprepitant. The average age
(mean±SD) of the breast cancer cohort was 53.2±9.8 years.
The average cyclophosphamide dose per square meter per
chemotherapy cycle was 414.1±343.3 mg, and the average
CCI score was 0.5±1.0. The average number of claims of
all antiemetics was 9.8±5.4 and was 7.7±4.1 when only the
207,396 patients with breast cancer diagnosis and had enrolled for at least 
6 months before the diagnosis were identified from PharMetrics database 
Received breast cancer surgery? 
65,239 patients remained 
Had at least 6 months follow-up period after the 
index chemotherapy date? 
17,968 patients remained 
Received cyclophosphamide-based chemotherapy during 2005 to 2008, 
>=18 years old, without CINV history before index chemotherapy, and 
had received 5-HT3 RAs during the index chemotherapy? 
5,654 patients remained 
4,868 patients remained 
Received chemotherapy within 4 months after surgery? 
Fig. 1 Selection of patients in
the breast cancer cohort
Support Care Cancer (2012) 20:941–949 9435-HT3 RAs were counted. In the 6-month post-index date
study duration, most patients with breast cancer received
either four (71.9%) or six chemotherapy cycles (13.0%).
Among the breast cancer cohort, 1,864 (38.3%)
belonged to the palonosetron-only group. As compared to
the other 5-HT3 RA group, the palonosetron-only group
was significantly older (53.7±10.0 years vs. 53.0±
9.7 years), received a higher average cyclophosphamide
dose (milligrams per square meter per cycle, 430.8±335.5
vs. 403.7±347.6), with fewer antiemetic claims (8.3±4.6
vs. 10.8±5.6) or 5-HT3 RA-only claims (6.2±3.4 vs. 8.5±
4.4); all differences were statistically significant (p<0.05;
Table 1). The two comparison groups had comparable CCI
score (0.5±1.0 vs. 0.5±1.1).
The carboplatin-treated lung cancer cohort consisted of
5,414 patients, with 66.6% treated with 5-HT3 RA
antiemetic prophylaxis only, 29.0% treated with 5-HT3
RAs in combination with dexamethasone, 1.6% treated
with 5-HT3 RAs combined with aprepitant, and 2.8%
treated with a combined regimen of 5-HT3 RAs, dexameth-
asone and aprepitant. This cohort had an average age of
64.6±10.2 years, with 2,518 (46.5%) females, and an
average CCI score of 6.8±3.2. Average days on carboplatin
treatment were 6.2±3.7. Average number of claims for all
antiemetics was 10.6±6.7, with an average of 9.6±6.0
when only the 5-HT3 RAs were considered.
One third (33.4%) of the patients with lung cancer
treated with carboplatin was in the palonosetron-only
group. The palonosetron-only group was significantly older
(65.0±10.3 years vs. 64.4±10.1 years), had significantly
fewer antiemetic claims (8.5±5.4 vs. 11.7±7.1) or 5-HT3
RA claims (7.7±4.9 vs. 10.5±6.3), and lower CCI score
(6.7±3.3 vs. 6.9±3.2); all p<0.05; (Table 1) versus the
other 5-HT3 RA group.
163,095 patients with lung cancer diagnosis identified 
from PharMetrics database 
Treated with cisplatin or carboplatin between 2005-2008? 
19,328 patients remained 
Had enrolled and remained enrolled for at least 6 months before and 
after the index date? 
10,916 patients remained 
Treated with 5-HT3 RA during the index chemotherapy with 
carboplatin or cisplatin? 
10,660 patients remained 
10,657 patients remained 
≥18 years old? 
No CINV history? 
8,200 patients remained 
• 7,112 patients did not have any chemotherapy within 6 
months before the index chemotherapy  
• 1,088 patients had chemotherapy before.  
No chemotherapy history? 
7,112 patients remained 
• 5,414 patients treated with carboplatin  
• 1,692 patients treated with cisplatin. 
• 6 patients treated with both carboplatin and cisplatin were 
excluded. 
Fig. 2 Selection of patients in
the two lung cancer cohorts
944 Support Care Cancer (2012) 20:941–949There were 1,692 patients identified with lung cancer on
cisplatin therapy. Among these, 46.8% were treated with 5-
HT3 RA antiemetic prophylaxis only, 20.1% treated with 5-
HT3 RAs in combination with dexamethasone, 13.6%
treated with 5-HT3 RAs in combination with aprepitant,
and 19.3% treated with a combination regimen of 5-HT3
RAs, dexamethasone and aprepitant. This cohort had an
average age of 60.2±9.6 years, 682 (40.3%) females, and
an average CCI score of 6.5±3.2. The average cisplatin
treatment days throughout the study were 5.6±4.2. The
average numbers of claims of all antiemetics were 13.3±7.8
and 11.1±6.6 when only the 5-HT3 RAs were counted.
A total of 390 (23.0%) patients in the cisplatin-treated lung
cancer cohort belonged to the palonosetron-only group. The
palonosetron-only group was significantly older than the other
5-HT3RA regimen group (61.3±9.8 years vs. 59.9±9.5 years),
incurred significantly fewer antiemetic claims (8.5±5.6 vs.
1 4 . 7 ± 7 . 8 )o r5 - H T 3 RA claims (6.4±4.4 vs. 12.4±6.5), with
fewer cisplatin treatment days (4.9±3.2 vs. 5.7±4.4). There
were significantly fewer females in the palonosetron-only
group (33.3% vs. 42.4%; all p<0.05, Table 1).
Antiemetic combination use by comparison groups
In all three cohorts, higher proportions of patients in the
palonosetron-only group were treated without adding aprepi-
tant, dexamethasone, or both. In the breast cancer cohort,
46.1% of the patients in the palonosetron-only group were
treatedwithpalonosetrononly,asopposedto41.3%whoused
any other 5-HT3 RA agent in the other 5-HT3 RA regimen
group (p<0.0001). Similarly, in the carboplatin-treated lung
cancer cohort, 72.9% of the patients in the palonosetron-only
group were treated with palonosetron only, as opposed to
63.4% in the other group (p<0.0001). Among the cisplatin-
treated lung cancer cohort, 51.0% in the palonosetron-only
treated group used palonosetron as the sole antiemetic, as
opposed to 45.6% in the other group (p=0.1170, Table 2).
Unadjusted risk for CINV
In the 6-month study follow-up period, 3.5% of the patients
withbreastcancerinthepalonosetron-onlygroupexperienced
≥1hospital/ED-associatedCINVeventsasopposedto6.3%in
the other group, p<0.0001. Among the carboplatin-treated
lung cancer cohort, the proportions were 9.5% and 13.8% for
the two groups, respectively, p<0.0001. A similar pattern
was observed in the cisplatin-treated lung cancer cohort, with
proportions of 16.4% and 22.6% (p=0.0089).
Adjusted risk for CINV
In the breast cancer cohort, multivariate logistic regres-
sion analysis showed that the palonosetron-only group
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Support Care Cancer (2012) 20:941–949 945experienced a significantly lower risk (45%) for a
hospital/ED-associated CINV event as compared to the
other 5-HT3 RA group (OR, 0.550; 95% CI: 0.412–0.733;
p<0.0001; Table 3). Older age significantly reduced risk
of outcome (OR, 0.984, 95% CI: 0.971–0.997, p=0.0196)
while higher CCI score significantly increased the risk
(OR, 1.271; 95% CI: 1.168–1.384, p<0.001).
In the carboplatin-treated lung cancer cohort, the
palonosetron-only group showed a significantly lower risk
(35%) of CINVevents (OR, 0.653; 95% CI: 0.543–0.785; p
<0.0001). Higher CCI score significantly increased the risk
of CINV (OR, 1.028; 95% CI, 1.002–1.054, p=0.0361),
whereas more carboplatin treatment days reduced the risk
(OR, 0.952; 95% CI, 0.929–0.976, p=0.0001). Similar
findings were observed in the cisplatin-treated lung cancer
cohort, with the palonosetron-only group experiencing
significantly lower risk for a CINV event (OR, 0.689,
95% CI: 0.510–0.931; p=0.0152). Higher CCI scores
significantly increased the risk of CINV (OR, 1.041, 95%
CI: 1.003–1.080; p=0.0319; Table 3).
Results from the current study and the four published
phase III clinical trials [2, 8–10] comparing palonosetron
and older 5-HT3 RAs are summarized in Table 4. Based on
the complete response rate of CINV in the overall study
period reported in the clinical trials, the computed relative
risks of CINV events for the palonosetron group versus the
other comparison groups ranged from 0.618 to 0.884. Also,
the computed relative risk reductions ranged between
11.6% and 38.2% for the palonosetron group versus the
older 5-HT3 RAs. The relative risk reductions ranged from
25.9% to 43.4% in the current study.
Discussion
To our knowledge, this study is the first to investigate the
comparative effectiveness of palonosetron-only as the 5-HT3
RA treatment versus other 5-HT3 RA treatment regimens
using claims from a large database compiled from real-world
clinical practice. Results indicated that among patients with
breast or lung cancer on HEC or MEC, those initiated and
maintained with palonosetron throughout the chemotherapy
treatment cycles experienced a significantly reduced risk of
hospital/ED-associated CINVevents, as compared to patients
who received other 5-HT3 RA-based regimens.
Results of this retrospective cohort study corroborate
data obtained from earlier published clinical trials. The
clinical trials and real-world community setting practice
Table 2 Distribution of patients by use of 5-HT3 RA alone or in combination with other antiemetics
Breast cancer Carboplatin-treated lung cancer Cisplatin-treated lung cancer
5-HT3 RA combinations Palonosetron-
only group, N
(%)
Other 5-HT3 RA
regimen group, N
(%)
Palonosetron-
only group, N
(%)
Other 5-HT3 RA
regimen group, N
(%)
Palonosetron-
only group, N
(%)
Other 5-HT3 RA
regimen group, N
(%)
5-HT3 RA only 860 (46.1) 1240 (41.3) 1316 (72.9) 2,289 (63.4) 199 (51.0) 593 (45.6)
5-HT3 RA+dexamethasone 386 (20.7) 830 (27.6) 433 (24.0) 1,138 (31.5) 65 (16.7) 278 (21.6)
5-HT3 RA+aprepitant 254 (13.6) 318 (10.6) 26 (1.4) 61 (1.7) 56 (14.4) 174 (13.4)
5-HT3 RA+dexamethasone
+aprepitant
364 (19.5) 616 (20.5) 31 (1.7) 120 (3.3) 70 (18.0) 257 (19.7)
Table 3 Multivariate logistic regression results on risks of CINV-associated hospitalization or ED visits between palonosetron-only and other 5-
HT3 RA regimen groups
Breast cancer Carboplatin-treated lung cancer Cisplatin-treated lung cancer
Parameter OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age 0.984 (0.971–0.997) 0.0196 1.003 (0.995–1.011) 0.5063 0.991 (0.979–1.004) 0.1710
Female gender NA 0.865 (0.734–1.019) 0.0830 1.177 (0.928–1.494) 0.1788
CCI 1.271 (1.168–1.384) <0.0001 1.028 (1.002–1.054) 0.0361 1.041 (1.003–1.080) 0.0319
Cyclophosphamide dose 1.000 (1.000–1.001) 0.2044 NA NA
Carboplatin/cisplatin
treatment days
NA 0.952 (0.929–0.976) 0.0001 0.980 (0.952–1.010) 0.1930
Palonosetron-only 0.550 (0.412–0.733) <0.0001 0.653 (0.543–0.785) <0.0001 0.689 (0.510–0.931) 0.0152
The reference group was male gender and treated with other 5-HT3 RA regimens
946 Support Care Cancer (2012) 20:941–949data indicate that prophylaxis and treatment with palonose-
tron was associated with a significant risk reduction for
more severe CINVevents. Although this study focused only
on CINV events associated with admission to emergency
departments or hospitals as opposed to all CINV events
reported in clinical trials, the relative risk reductions
reported here are comparable to those reported in these
trials. More specifically, the relative risk reductions com-
puted from the four trials ranged between 11.6% and 38.2%
for the palonosetron group as compared to the older 5-HT3
RAs. This study focused on the more severe CINV events,
while the clinical trials conducted with palonosetron
reported on all CINV events. In spite of the difference in
severity of CINV between this study and the earlier
conducted clinical trials, our calculated relative risk
reductions ranging between 25.9% and 43.4% were in line
with the trials’ data. Additionally, a recently published
study using medical record review reported that patients
with gynecological cancer treated with cisplatin when
prophylaxed with palonosetron experienced a lower risk
of CINV-related hospital readmission versus patients
prophylaxed with ondansetron [14].
Depending on the chemotherapy regimens, cyclophos-
phamide is given in a dose of 300–600 mg/m
2 as adjuvant
therapy to patient with breast cancer [15]. The average dose
of cyclophosphamide used in the breast cancer cohort was
at the lower end of the dosing range, which might imply
that our study cohort might have a less severe clinical status
than patients with breast cancer receiving higher doses of
cyclophosphamide. As such, one might anticipate that the
impact of palonosetron on CINV may be more pronounced
if a patient cohort with more intense chemotherapy
regimens was studied. There were additional noteworthy
clinical differences between the two comparison groups. In
the breast cancer cohort, patients on palonosetron-only
received, on average, 27 mg/m
2 (or 7%) higher cyclophos-
phamide dose per treatment cycle than the dose received by
patients treated with the other 5-HT3 RA regimens. One of
the plausible explanations of this finding maybe that patients
who received palonosetron-only were better able to tolerate
Table 4 Comparison of treatment effect of palonosetron from clinical trials and the current study
Studies Method Type of
cancer
CT
agent
Comparisons CR rate of CINV
in overall phase
Computed CINV
rate (1-CR)
Computed
ARR
a
Computed
relative
risk
b
Computed
RRR
c
Aapro
2 Phase III
RCT
Various HEC Palo 0.25 mg vs.
ondan
40.8% vs. 33.0% 59.2% vs. 67.0% 7.8% 0.884 11.6%
Palo 0.75 mg vs.
ondan
42.2% vs. 33.0% 57.8% vs. 67.0% 9.2% 0.863 13.7%
Palo 0.25 mg+dex
vs. ondan+dex
40.7% vs. 25.2% 59.3% vs. 74.8% 15.5% 0.793 20.7%
Eisenberg
9 Phase III
RCT
Various MEC Palo 0.25 mg vs. dola 46.0% vs. 34.0% 54.0% vs. 66.0% 12.0% 0.818 18.2%
Palo 0.75 mg vs. dola 47.1% vs. 34.0% 52.9% vs. 66.0% 13.1% 0.802 19.8%
Gralla
8 Phase III
RCT
Various MEC Palo 0.25 mg vs.
ondan
69.3% vs. 50.3% 30.7% vs. 49.7% 19% 0.618 38.2%
Palo 0.75 mg vs.
ondan
58.7% vs. 50.3% 41.3% vs. 49.7% 8.4% 0.831 16.9%
Saito
10 Phase III
RCT
Various HEC Palo+dex 0.75 mg
vs. grani+dex
51.5% vs. 40.4% 48.5% vs. 59.6% 11.1% 0.814 18.6%
Current Outcomes
research
BC MEC Palo only vs. other 5-
HT3 RA regimens
NA 3.5% vs. 6.3%
d 2.8%
e 0.566
f 43.4%
Carboplatin-
treated LC
MEC Palo only vs. other 5-
HT3 RA regimens
NA 9.5% vs. 13.8% 4.3% 0.599 40.1%
Cisplatin-
treated LC
HEC Palo only vs. other 5-
HT3 RA regimens
NA 16.4% vs. 22.6% 6.2% 0.741 25.9%
CR complete response, CT chemotherapy, Palo palonosetron, ondan ondansetron, grani granisetron, dex dexamethasone, BC breast cancer, LC
lung cancer, MEC moderately emetogenic chemotherapy, HEC highly emetogenic chemotherapy, ARR absolute risk reduction, RRR relative risk
reduction
aARR=CINV rate of (comparative drug–palonosetron)
bRelative risk=CINV rate of (palonosetron/comparative drug)
c RRR=1-RR
dEmergency room or hospital-associated CINV events
eUnadjusted ARR
fBased on adjusted odds ratios and computation method from Zhang and Yu [13]
Support Care Cancer (2012) 20:941–949 947higher cyclophosphamide doses. This finding is relevant to
the extent that high and moderate-dose intensity regimens
were reported to result in significantly better disease-free
survival and overall survival than the low-dose intensity
regimens [16]. Similarly, the palonosetron-only group of the
lung cancer cohorts needed fewer total CT days (cisplatin-
treated lung cancer, 4.9 days vs. 5.7 days, p<0.0001;
carboplatin-treated lung cancer, 6.1 days vs. 6.2 days, p>
0.05) to complete their chemotherapy regimens. One of the
plausible explanations, based on the study findings, is that
patients who received the palonosetron-only regimen may
have been better able to complete their chemotherapy
treatment regimen within fewer days, in light of their CINV
experience. The results of the logistic regressions support our
contention. Patients with more CT days showed a lower risk
of CINV, indicating that spreading CT over more days, and
thus potentially lowering the dose given per day, might have
been a strategy used to reduce the burden of CINV. Further
comparative studies are required to investigate whether the
differences seen between the two study groups in chemo-
therapy doses/days may in fact impact patients’ clinical
status or result in some economic efficiency.
The proportion of patients who used a 5-HT3 RA alone
without adding dexamethasone and/or aprepitant was higher
in the palonosetron-only group. It is important to note that
the pattern of antiemetic utilization observed in this analysis
did not conform to the recommendations of the major CINV
guidelines. The ASCO, MASCC-ESMO, and NCCN guide-
lines all recommend utilizing doublet therapy (dexametha-
sone and a 5-HT3 RA) for MEC and a triplet regimen
(dexamethasone, a 5-HT3 receptor antagonist and an NK1
R A )f o rH E Ca sw e l la sa n t h r a c y c l i n e –cyclophosphamide
chemotherapy. In this analysis, single-agent 5-HT3 RA
therapy was received by 43% of breast cancer patients,
67% of carboplatin-treated patients and 47% of cisplatin-
treated patients. Furthermore, only 19% of cisplatin-treated
lung cancer patients received triple therapy. These findings
suggest that undertreatment with antiemetics was widespread
during this period and the number of visits to the ED could
be improved with a higher percentage of patients adhering to
the current CINV prevention guidelines.
Although a triplet regimen of dexamethasone, palonose-
tron,andaprepitanthasbeenshowntobeaneffectiveregimen
for emesis prevention [17–19], whether palonosetron would
similarly improve upon the results relative to other 5-HT3
RA regimens when evaluated in a population of patients who
all received the recommended standard triplet antiemetic
therapy remains an important question. The patient numbers
from the current study were insufficient to carry out this type
of analyses. However, a recent retrospective claims data
analysis in over 4,000 patients all receiving a triplet regimen
suggests that a difference persists even when guideline
recommended regimens are given [20]. The triplet regimen
that included palonosetron was associated with a lower risk
for an uncontrolled CINVevent than the triplet regimen that
included an older 5-HT3 RA. Further prospective studies are
warranted to further clarify an answer to this question [20].
In this study, we did not differentiate the individual first
generation 5-HT3 RAs used, in part, to simplify the study
design, and also based on an earlier report of no significant
difference between the antiemetic efficacy of dolasetron,
granisetron, or ondansetron in controlling CINV in patients
on platinum-based chemotherapy regimens [21].
Finally, our ability to identify CINV depended on the
availability of unique identifiers such as ICD-9-CM or CPT
codes. As such, this study focused on CINV events
resulting in ED or hospitalization episodes needed to
manage these events without being able to address the
significant negative impact of CINV events on patients’
health-related quality of life.
Limitations
The calculations of the actual doses used in the various
chemotherapy regimens depended on the level of details
provided by HCPCS codes. There were 11 unique HCPCS
codes to identify cyclophosphamide. In contrast, there were
only one or two HCPCS codes for cisplatin or carboplatin,
respectively. The lack of HCPCS codes did not allow the
calculation of the actual doses for carboplatin/cisplatin
consumed, or the further delineation of the relationship
between chemotherapy dose and 5-HT3 RA utilization
patterns in the two cohorts of patients with lung cancer.
Moreover, this study had the inherent limitations associated
with retrospective analyses using claims database, such as
the potential for selection bias. While CCI and multiple
regressions were employed to adjust for the differences
between comparison groups, it is not possible to ascertain
whether the adjustment was sufficient to account for all the
selection bias. Additionally, other factors that would be
relevant to CINV outcomes, such as staging of the cancer,
race, alcohol consumption, and smoking history were not
available. The study analysis was based on an intent-to-treat
principle, thereby not allowing for the estimation of
chemotherapy or antiemetic medication discontinuation
rates, or for dose adjustment, or medication adherence.
Finally, the database used in this study was employer-
based, thus potentially limiting the generalizability of the
study findings.
Conclusions
The results from this real-world claims database corroborate
clinical trial findings. This study showed that initiating and
maintaining patients on a palonosetron-only 5-HT3 RA-
948 Support Care Cancer (2012) 20:941–949based regimen reduced the risk of hospital/ED-associated
CINV events in female breast cancer undergoing MEC
adjuvant therapy post-surgical interventions. Similar results
were also demonstrated in lung cancer patients treated with
either MEC or HEC. Further studies are warranted on the
overall comparative effectiveness of the individual antie-
metics and their combined use on CINV outcomes and on
patients’ health-related quality of life.
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